Journal for ImmunoTherapy of Cancer – Page 77

A crisis in clinical research

11 de July de 2024 by Hong, D. S., LoRusso, P., Sznol, M.

The clinical research pipeline is critical to ensuring continued development of novel treatments that can offer patients with cancer safe and effective options. Unfortunately, progress has slowed since the COVID-19 pandemic due to uncovered, systemic …

Correction: ASCC3 promotes the immunosuppression and progression of non-small cell lung cancer by impairing the type I interferon response via CAND1-mediated ubiquitination inhibition of STAT3

10 de July de 2024 by Journal for ImmunoTherapy of Cancer current issue

Harnessing lipid metabolism modulation for improved immunotherapy outcomes in lung adenocarcinoma

9 de July de 2024 by Chen, Y., Zhou, Y., Ren, R., Chen, Y., Lei, J., Li, Y.

Background
While anti-programmed cell death protein-1 (PD-1) monotherapy has shown effectiveness in treating lung cancer, its response rate is limited to approximately 20%. Recent research suggests that abnormal lipid metabolism in patients with lung …

Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines

9 de July de 2024 by Schlom, J., Donahue, R. N., Palena, C., Gameiro, S. R., Hodge, J. W., Hamilton, D. H., Gulley, J. L.

The development of vaccines, especially RNA-based, directed against patient-specific tumor neoepitopes is an active and productive area of cancer immunotherapy. Promising clinical results in melanoma and other solid tumor types are emerging. As with a…

TCF1-positive and TCF1-negative TRM CD8 T cell subsets and cDC1s orchestrate melanoma protection and immunotherapy response

5 de July de 2024 by

Background
Melanoma, the most lethal form of skin cancer, has undergone a transformative treatment shift with the advent of checkpoint blockade immunotherapy (CBI). Understanding the intricate network of immune cells infiltrating the tumor and orchest…

Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids

5 de July de 2024 by Burri, E., Mangana, J., Cheng, P. F., Schneider, A., Weber, A., Dummer, R., Ramelyte, E.

Background
Immune-related hepatitis (irHepatitis) is a relatively common immune-related adverse event (irAE) of checkpoint inhibitors. Often, it responds well to steroids; however, in refractory cases, further therapy is needed. Anti-tumor necrosis fa…

Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations

4 de July de 2024 by

Background
OX40 has been widely studied as a target for immunotherapy with agonist antibodies taken forward into clinical trials for cancer where they are yet to show substantial efficacy. Here, we investigated potential mechanisms of action of anti-m…

Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8+ TILs based on BRCA1/2 mutation status in epithelial ovarian cancers

4 de July de 2024 by Park, J., Kim, J. C., Lee, Y. J., Kim, S., Kim, S. W., Shin, E.-C., Lee, J. Y., Park, S.-H.

Background
We aimed to investigate the distinct immunological characteristics of the tumor immune microenvironment in epithelial ovarian cancer (EOC) according to BRCA1/2 mutations status and differential PD-1 expression levels.

Methods
Tumor-infiltr…

Hypoxia inhibits the iMo/cDC2/CD8+ TRMs immune axis in the tumor microenvironment of human esophageal cancer

4 de July de 2024 by Wu, C., Yu, H., Liang, F., Huang, X., Jiang, B., Lou, Z., Liu, Y., Wu, Z., Wang, Q., Shen, H., Chen, M., Wu, P., Wu, M.

Background
Esophageal cancer (ESCA) is a form of malignant tumor associated with chronic inflammation and immune dysregulation. However, the specific immune status and key mechanisms of immune regulation in this disease require further exploration.

M…

Off-the-shelf CAR-NK cells targeting immunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatin

4 de July de 2024 by Zheng, L., Wang, H., Zhou, J., Shi, G., Ma, J., Jiang, Y., Dong, Z., Li, J., He, Y.-Q., Wu, D., Sun, J., Xu, C., Li, Z., Wang, J.

Background
Chimeric antigen receptor natural killer (CAR-NK) therapy holds great promise for treating hematologic tumors, but its efficacy in solid tumors is limited owing to the lack of suitable targets and poor infiltration of engineered NK cells. H…